{"entity":{"id":"nct04547166","kind":"trial","name":"A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Meta","aka":[],"tldr":"A phase 2/3 trial of Serplulimab, Bevacizumab in colorectal cancer, run by Shanghai Henlius Biotech, now recruiting.","summary":"A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) is a phase 2/3 interventional study registered as NCT04547166 by Shanghai Henlius Biotech, with 568 participants planned, started 2021-03-10 and due to reach its primary completion in 2025-09-24. Interventions recorded: HLX10, HLX04、. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04547166","url":"https://clinicaltrials.gov/study/NCT04547166"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","monoclonal-antibody"],"targets":[],"drugs":["serplulimab","bevacizumab"],"companies":["henlius"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct04547166-med-2024"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04547166","phase":"2/3","setting":"A Randomized, Double-blind, Multicenter, PhaseⅡ/Ⅲ Clinical Study of Serplulimab in Combination With Bevacizumab and Chemotherapy (XELOX) Versus Placebo in Combination With Bevacizumab and Chemotherapy (XELOX) in First-line Treatment of Patients With Metastatic Colorectal Cancer (mCRC)","sponsor":"Shanghai Henlius Biotech","started":"2021-03-10","startedType":"actual","enrolled":568,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04547166/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/"}],"company":[{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/"}],"paper":[{"id":"paper-nct04547166-med-2024","kind":"paper","name":"First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial","route":"/key-papers/paper-nct04547166-med-2024/"}]}}